Boston Scientific Corporation (NYSE:BSX) SVP David A. Pierce sold 8,763 shares of Boston Scientific stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $27.74, for a total transaction of $243,085.62. Following the transaction, the senior vice president now owns 24,201 shares in the company, valued at approximately $671,335.74. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Boston Scientific Corporation (NYSE:BSX) opened at $27.39 on Friday. Boston Scientific Corporation has a 52 week low of $23.29 and a 52 week high of $29.93. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. The company has a market cap of $37,941.41, a PE ratio of 391.29, a P/E/G ratio of 1.98 and a beta of 0.81.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. The company had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.39 billion. During the same quarter in the prior year, the company posted $0.30 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. analysts predict that Boston Scientific Corporation will post 1.37 earnings per share for the current year.
Several research analysts have recently weighed in on the stock. Jefferies Group reiterated a “neutral” rating on shares of Boston Scientific in a research note on Friday. Zacks Investment Research upgraded shares of Boston Scientific from a “sell” rating to a “hold” rating in a research report on Tuesday. TheStreet upgraded shares of Boston Scientific from a “c+” rating to a “b” rating in a research report on Thursday, January 18th. Barclays restated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research report on Wednesday, January 10th. Finally, Canaccord Genuity restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, January 17th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $31.00.
Several hedge funds and other institutional investors have recently bought and sold shares of BSX. Schroder Investment Management Group increased its stake in shares of Boston Scientific by 3.2% during the 2nd quarter. Schroder Investment Management Group now owns 275,180 shares of the medical equipment provider’s stock valued at $7,656,000 after acquiring an additional 8,623 shares during the last quarter. Private Advisor Group LLC increased its position in Boston Scientific by 26.6% during the 2nd quarter. Private Advisor Group LLC now owns 19,376 shares of the medical equipment provider’s stock worth $534,000 after purchasing an additional 4,069 shares in the last quarter. Commonwealth Bank of Australia increased its position in Boston Scientific by 8.7% during the 2nd quarter. Commonwealth Bank of Australia now owns 73,572 shares of the medical equipment provider’s stock worth $2,038,000 after purchasing an additional 5,919 shares in the last quarter. CIBC World Markets Inc. acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $663,000. Finally, Financial Counselors Inc. acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $209,000. 90.59% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/03/boston-scientific-corporation-bsx-svp-david-a-pierce-sells-8763-shares.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.